Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells

DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation

(2018) Qian Xiao et al.   NATURE MEDICINE

Genetic Mechanisms of Immune Evasion in Colorectal Cancer

(2018) Catherine S. Grasso et al.   Cancer Discovery

Immunotherapy for Colorectal Cancer

(2017) Patrick Boland et al.   Cancers

Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)

(2016) J. M. Kim et al.   ANNALS OF ONCOLOGY

Structure-Based Design of 1,4-Dibenzoylpiperazines as β-Catenin/B-Cell Lymphoma 9 Protein–Protein Interaction Inhibitors

(2016) John A. Wisniewski et al.   ACS Medicinal Chemistry Letters

AlphaScreen selectivity assay for β-catenin/B-cell lymphoma 9 inhibitors

(2015) Min Zhang et al.   ANALYTICAL BIOCHEMISTRY

Rational Design of Selective Small-Molecule Inhibitors for β-Catenin/B-Cell Lymphoma 9 Protein–Protein Interactions

(2015) Logan R. Hoggard et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype

(2015) Gyu-Beom Jang et al.   Scientific Reports

CCL20/CCR6-mediated migration of regulatory T cells to theHelicobacter pylori-infected human gastric mucosa

(2014) Katherine W Cook et al.   GUT

Can we safely target the WNT pathway?

(2014) Michael Kahn   NATURE REVIEWS DRUG DISCOVERY

A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation-Driven Colorectal Tumor Growth

(2013) T. Lau et al.   CANCER RESEARCH

Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy

(2013) Melissa G. Lechner et al.   JOURNAL OF IMMUNOTHERAPY

Wnt Signaling Pathway in Non-Small Cell Lung Cancer

(2013) D. J. Stewart   JNCI-Journal of the National Cancer Institute

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

(2013) Yong S. Chang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TGF-β-miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma

(2012) Pengyuan Yang et al.   CANCER CELL

Wnt/β-Catenin Signaling and Disease

(2012) Hans Clevers et al.   CELL

Drugging Wnt signalling in cancer

(2012) Paul Polakis   EMBO JOURNAL

Targeted Disruption of the BCL9/ -Catenin Complex Inhibits Oncogenic Wnt Signaling

(2012) K. Takada et al.   Science Translational Medicine

An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid

(2012) Marc de la Roche et al.   Nature Communications

Protein transduction domain delivery of therapeutic macromolecules

(2011) Arjen van den Berg et al.   CURRENT OPINION IN BIOTECHNOLOGY

Design of Triazole-Stapled BCL9 α-Helical Peptides to Target the β-Catenin/B-Cell CLL/lymphoma 9 (BCL9) Protein–Protein Interaction

(2011) Steven A. Kawamoto et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bcl9/Bcl9l Are Critical for Wnt-Mediated Regulation of Stem Cell Traits in Colon Epithelium and Adenocarcinomas

(2010) J. Deka et al.   CANCER RESEARCH

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

(2010) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL INVESTIGATION

Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic

(2010) G. H. Bird et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BCL9 Promotes Tumor Progression by Conferring Enhanced Proliferative, Metastatic, and Angiogenic Properties to Cancer Cells

(2009) M. Mani et al.   CANCER RESEARCH

Central Role of Tumor-Associated CD8+ T Effector/Memory Cells in Restoring Systemic Antitumor Immunity

(2009) M. O. Kilinc et al.   JOURNAL OF IMMUNOLOGY

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

(2008) Alberto F. Sobrero et al.   JOURNAL OF CLINICAL ONCOLOGY